The short version of circadian rhythm fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-01 and is reviewed periodically as new material appears.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Rates of severe hypoglycemia have generally declined due to the advent of rapid-acting and long-acting insulin products in the 1990s and early 2000s; however, acute hypoglycemia still causes 4–10% of type 1 diabetes-related deaths. The other persistent risk is diabetic ketoacidosis – a state where lack of insulin results in cells burning fat rather than sugar, producing toxic ketones as a byproduct. Ketoacidosis symptoms can develop rapidly, with frequent urination, excessive thirst, nausea, vomiting, and severe abdominal pain all common. More severe ketoacidosis can result in labored breathing, and loss of consciousness due to cerebral edema. People with type 1 diabetes experience diabetic ketoacidosis 1–5 times per 100 person-years, the majority of which result in hospitalization. 13–19% of type 1 diabetes-related deaths are caused by ketoacidosis, making ketoacidosis the leading cause of death in people with type 1 diabetes less than 58 years old.
==== Male reproductive system ==== The effect of estradiol (and estrogens in general) upon male reproduction is complex. Estradiol is produced by action of aromatase mainly in the Leydig cells of the mammalian testis, but also by some germ cells and the Sertoli cells of immature mammals. It functions (in vitro) to prevent apoptosis of male sperm cells. While some studies in the early 1990s claimed a connection between globally declining sperm counts and estrogen exposure in the environment, later studies found no such connection, nor evidence of a general decline in sperm counts. Suppression of estradiol production in a subpopulation of subfertile men may improve the semen analysis. Males with certain sex chromosome genetic conditions, such as Klinefelter's syndrome, will have a higher level of estradiol.
A conviction for trafficking heroin carries the death penalty in most Southeast Asian, some East Asian and Middle Eastern countries (see Use of death penalty worldwide for details), among which Malaysia, Singapore and Thailand are the strictest. The penalty applies even to citizens of countries where the penalty is not in place, sometimes causing controversy when foreign visitors are arrested for trafficking, for example, the arrest of nine Australians in Bali, the death sentence given to Nola Blake in Thailand in 1987, or the hanging of an Australian citizen Van Tuong Nguyen in Singapore.
Langlykke who visited the Argentine lab once a year. In 1960, he offered Ondetti a job to work in the New Jersey laboratory. Within two days, Ondetti decided to take the job in New Jersey for $7800 a year.
Menthol is a monoterpenoid organic compound that occurs naturally in the oils of certain plants in the mint family, such as corn mint and peppermint. It is a white or clear waxy crystalline substance that is solid at room temperature and melts slightly above. The main form of menthol occurring in nature is (−)-menthol, which is assigned the (1R,2S,5R) configuration. For many people, menthol produces a cooling sensation when inhaled, eaten, or applied to the skin, and mint plants have been used for centuries for topical pain relief and as a food flavoring. Menthol has local anesthetic and counterirritant qualities, and it is widely used to relieve minor throat irritation. Menthol has been demonstrated to cause a subjective nasal decongestant effect without any objective decongestant action, and administration of menthol via a nasal inhaler in humans has also been shown to cause nasal decongestion.
Sources: en.wikipedia.org
Andexanet alfa, sold under the brand name Andexxa among others, is an antidote for the medications rivaroxaban and apixaban, when reversal of anticoagulation is needed due to uncontrolled bleeding. It has not been found to be useful for other factor Xa inhibitors. It is given by injection into a vein. Common side effects include pneumonia and urinary tract infections. Severe side effects may include blood clots, heart attacks, strokes, or cardiac arrest. It works by binding to rivaroxaban and apixaban. It was approved for medical use in the United States in May 2018. It was developed by Portola Pharmaceuticals. In December 2025, the FDA issued a drug safety communication in response to postmarketing safety data on thromboembolic events, including serious and fatal outcomes, and determined that the risks of the medication outweigh the benefits. In response, AstraZeneca submitted a request to voluntarily withdraw the Biologics License Application and end commercial sales and manufacturing in the United States by December 22, 2025.
== History == The modern understanding of the pathway of glycolysis took almost 100 years to fully learn. The combined results of many smaller experiments were required to understand the entire pathway. The first steps in understanding glycolysis began in the 19th century. For economic reasons, the French wine industry sought to investigate why wine sometimes turned distasteful, instead of fermenting into alcohol. The French scientist Louis Pasteur researched this issue during the 1850s. His experiments showed that alcohol fermentation occurs by the action of living microorganisms, yeasts, and that glucose consumption decreased under aerobic conditions (the Pasteur effect).
== Death == Kimon Georgiev died suddenly of a stroke at around 1 pm on 28 September 1969 at the rest station of the Council of Ministers in Varna, shortly after visiting the Varna Thermal Power Plant, which had opened a month earlier. He was buried on 30 September in the Central Sofia Cemetery with state honours, with Prime Minister Todor Zhivkov attending the ceremony.
== Function == This gene encodes a protein that belongs to the microtubule-associated protein family. The proteins of this family are thought to be involved in microtubule assembly, which is an essential step in neurogenesis. The product of this gene is a precursor polypeptide that presumably undergoes proteolytic processing to generate the final MAP1B heavy chain and LC1 light chain. Gene knockout studies of the mouse microtubule-associated protein 1B gene suggested an important role in development and function of the nervous system. Two alternatively spliced transcript variants have been described.
== Oncology == During the 2020s, scientists have turned one deadly amanitin produced by Amanita phalloides into a promising weapon against cancer. Once known only as the cause of fatal mushroom poisoning, this molecule is now used as the "payload" in a new type of targeted therapy called ATACs (α-amanitin-based antibody-drug conjugates). These drugs consist of a monoclonal antibody that seeks out cancer cells, linked to α-amanitin, which is released inside the tumor to destroy it. What makes α-amanitin especially effective is its unique way of working: it blocks RNA polymerase II, the enzyme that cells use to read their DNA and produce essential proteins. Unlike most chemotherapy drugs, it acts independently of the cell cycle, so it can kill not only rapidly dividing cancer cells but also the slow-growing or "dormant" cancer stem cells that often survive standard treatments and cause relapse. The most advanced candidate is HDP-101 (pamlectabart tismanitin), developed by Heidelberg Pharma. It targets the BCMA protein on multiple myeloma cells. In the ongoing Phase I/IIa clinical trial (NCT04879043), the drug was safely escalated up to 218 µg/kg. It received FDA Fast Track designation in October 2025, and the recommended Phase II dose was chosen in April 2026. In the higher-dose groups (90–140 µg/kg), response rates ranged from 38 % to 57 %, with some heavily pretreated patients, including those who had already failed other BCMA-targeted therapies, achieving deep and lasting complete remissions of more than one year.
Sources: en.wikipedia.org
For a first-order reaction, the half-life of a reactant is independent of its initial concentration. Therefore, if the concentration of A at some arbitrary stage of the reaction is [A], then it will have fallen to 1/2[A] after a further interval of
=== Time resolved laser fluorescence spectroscopy === Time-resolved laser fluorescence spectroscopy is a sensitive spectroscopic method able to investigate the formation of different complex species in sub-micro molar concentrations. Thanks to the great spectroscopic properties of some metal cations representatives of actinides and lanthanides, fluorescence analyses by laser excitation of ion energy levels can be carried out on monophasic and biphasic solutions. The fluorescence evolution resulting from the ion energy transitions is generally followed as a function of ligand concentration in monophasic titration experiments. The bathochromic shift of the fluorescence spectra are due to the ligand complexation. According to the postulated complexation model and the Slope Analysis on the experimental data, the stoichiometry of the major complexes can be determined. Moreover, the cumulative stability constants
The molecular basis for genes is deoxyribonucleic acid (DNA). DNA is composed of deoxyribose (sugar molecule), a phosphate group, and a base (amine group). There are four types of bases: adenine (A), cytosine (C), guanine (G), and thymine (T). The phosphates make phosphodiester bonds with the sugars to make long phosphate-sugar backbones. Bases specifically pair together (T&A, C&G) between two backbones and make like rungs on a ladder. The bases, phosphates, and sugars together make a nucleotide that connects to make long chains of DNA. Genetic information exists in the sequence of these nucleotides, and genes exist as stretches of sequence along the DNA chain. These chains coil into a double a-helix structure and wrap around proteins called Histones which provide the structural support. DNA wrapped around these histones are called chromosomes. Viruses sometimes use the similar molecule RNA instead of DNA as their genetic material. DNA normally exists as a double-stranded molecule, coiled into the shape of a double helix. Each nucleotide in DNA preferentially pairs with its partner nucleotide on the opposite strand: A pairs with T, and C pairs with G. Thus, in its two-stranded form, each strand effectively contains all necessary information, redundant with its partner strand. This structure of DNA is the physical basis for inheritance: DNA replication duplicates the genetic information by splitting the strands and using each strand as a template for synthesis of a new partner strand.
=== Negotiations fail === Steyn of the Orange Free State invited Milner and Kruger to attend a conference in Bloemfontein. The conference started on 30 May 1899, but negotiations quickly broke down, as Kruger had no intention of granting meaningful concessions, and Milner had no intention of accepting his normal delaying tactics. On 9 October 1899, after convincing the Orange Free State to join him and mobilising their forces, Kruger issued an ultimatum giving Britain 48 hours to withdraw troops from the border of Transvaal, despite the fact the only regular British troops near the border of either republic were 4 companies deployed to defend Kimberley. Otherwise, the Transvaal, allied with the Orange Free State, would declare war. News of the ultimatum reached London on the day it expired. The editor of the Times purportedly laughed out loud when he read it, saying 'an official document is seldom amusing and useful yet this was both'. The Times denounced the ultimatum as an 'extravagant farce' and The Globe denounced this 'trumpery little state'. Most editorials were similar to the Daily Telegraph's, which declared: 'of course there can only be one answer to this grotesque challenge. Kruger has asked for war and war he must have!' Such views were far from those of the British government and the army. Army reform had been a matter of pressing concern since the 1870s, put off because the public did not want the expense of a larger, more professional army and because a large home army was not politically welcome.
Number of amino acid residues: 583 Molecular weight: 66,463 Da (= 66.5 kDa) isoelectric point in water at 25 °C: 4.7 Extinction coefficient of 43,824 M−1cm−1 at 279 nm Dimensions: 140 × 40 × 40 Å (prolate ellipsoid where a = b < c) pH of 1% Solution: 5.2-7 Optical Rotation: [α]259: -61°; [α]264: -63° Stokes Radius (rs): 3.48 nm Sedimentation constant, S20,W × 1013: 4.5 (monomer), 6.7 (dimer) Diffusion constant, D20,W × 10−7 cm2/s: 5.9 Partial specific volume, V20: 0.733 Intrinsic viscosity, η: 0.0413 Frictional ratio, f/f0: 1.30 Refractive index increment (578 nm) × 10−3: 1.90 Optical absorbance, A279 nm1 g/L: 0.667 ε280 = 43.824 mM−1 cm−1 Mean residue rotation, [m']233: 8443 Mean residue ellipticity: 21.1 [θ]209 nm; 20.1 [θ]222 nm Estimated a-helix, %: 54 Estimated b-form, %: 18
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.